| Description | Glenzocimab (ACT017) is a Fab fragment of a humanized anti-GPVI monoclonal antibody. Glenzocimab demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model. Glenzocimab has been studied in acute ischemic stroke and cerebral thrombosis. |
| In vitro | Glenzocimab (0-100,000 ng/mL) 在微量滴定板上固定的胶原蛋白中抑制了GPVI-Fc的结合，展现出了1.37 μg/mL[2]的IC50值。 |
| In vivo | Glenzocimab (1-8 mg/kg; i.v.) 在恒河猴中抑制了由胶原蛋白引起的血小板聚集[2]。 |
| Target activity | GPVI-Fc:1.37 μg/mL |
| Synonyms | ACT017 |
| molecular weight | N/A |
| CAS | 2101829-58-5 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53(11):3506-3513. 2. Lebozec K, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. MAbs. 2017 Aug/Sep;9(6):945-958. |